Does Medicare Cover GLP-1 Weight Loss Drugs in 2026?

Yes — for the first time, Medicare covers certain GLP-1 medications for weight loss through a new pilot that started July 1, 2026. The Medicare GLP-1 Bridge program gives eligible Part D plan members access to Wegovy (injection or tablet), Zepbound KwikPen, or Foundayo tablets for a $50 copayment per 30-day supply. This is a landmark shift, because Medicare had never before paid for these drugs when the goal was weight loss alone.

The Bridge program is temporary by design. It runs through December 31, 2027, acting as a stopgap until the BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) launches. One important limit: the pilot covers Wegovy tablets and injections, Zepbound KwikPens, and Foundayo tablets — but not single-dose Zepbound vials or pens. Coverage also depends on your specific Part D plan participating, so the practical first step is to confirm enrollment details with your plan. If you're weighing this against paying out of pocket, our guide to [GLP-1 savings cards and cash prices](/blog/glp1-savings-cards-cash-prices-lower-cost-2026) is a useful companion.

Medicare did not cover weight-loss drugs before 2026 because of a statutory exclusion written into Medicare Part D when it launched in 2006. That law specifically barred Part D from paying for medications used for weight loss, regardless of how effective they were. When GLP-1 drugs like Wegovy and Zepbound arrived and proved to drive 15–21% average weight loss in trials, this decades-old rule left millions of older adults unable to access them through Medicare.

The 2026 Bridge program works around that exclusion as a demonstration pilot rather than a permanent change to the statute. This is why it has an end date and why eligibility is narrower than commercial insurance. Understanding this history helps explain a confusing reality: the same drug can be covered for one person and denied for another, depending entirely on the *reason* it's prescribed. That distinction — indication versus weight loss — is the key to Medicare GLP-1 coverage, and it's covered in the next section.

Yes — Medicare Part D can cover these medications when they're prescribed for an approved medical condition other than weight loss. This has actually been true even before the 2026 Bridge program, and it remains one of the most common ways beneficiaries get coverage:

Ozempic may be covered when prescribed for type 2 diabetes and listed on your plan's formulary (drug list). It is not covered for weight loss. Wegovy may be covered to reduce the risk of cardiovascular death, heart attack, or stroke in adults with established cardiovascular disease who are also overweight or obese — an indication supported by the SELECT trial. Zepbound may be covered for moderate-to-severe obstructive sleep apnea in adults with obesity, following the SURMOUNT-OSA findings. In each case, your provider must document the qualifying diagnosis. If sleep apnea applies to you, our article on [GLP-1 and sleep apnea in menopause](/blog/glp1-sleep-apnea-menopause-surmount-osa-what-it-means) explains what SURMOUNT-OSA actually showed.

Eligibility for the Bridge program centers on being enrolled in a participating Medicare Part D plan and meeting the clinical criteria your plan sets. Because it's a pilot, not every plan participates, and the exact requirements can vary. Providers are generally expected to certify that you're using the GLP-1 as part of a comprehensive lifestyle program focused on diet and exercise — the medication is meant to complement those changes, not replace them.

The most reliable path is to call your Part D plan directly and ask three questions: Is my plan part of the GLP-1 Bridge program? Which of the covered drugs (Wegovy, Zepbound KwikPen, Foundayo) are on my formulary? And what documentation does my provider need to submit? Keep in mind the $50 copay applies per 30-day supply, so budget for it as an ongoing monthly cost. For those who don't qualify or whose plan doesn't participate, [telehealth GLP-1 providers](/blog/glp1-telehealth-providers-how-to-get-a-prescription-online-2026) and compounded options may fill the gap — though always weigh [compounded versus brand GLP-1](/blog/compounded-vs-brand-glp1-whats-the-difference) carefully.

When the Bridge program expires on December 31, 2027, Medicare plans to transition to the BALANCE Model — Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth. The BALANCE Model is designed as a longer-term framework for how Medicare approaches obesity treatment, pairing medication access with lifestyle and nutrition support rather than treating drugs in isolation.

Because these programs are still evolving, the specifics of BALANCE eligibility and covered drugs may change before it launches. The practical takeaway: coverage rules in this space are shifting quickly, so what's true in 2026 may look different by 2028. If you rely on Medicare for your GLP-1, it's worth checking your plan's coverage each open enrollment period and staying in touch with your prescriber about your options. Lea can help you track how your medication fits into the bigger picture of your health — including the muscle, bone, and nutrition needs that matter most as you age on these drugs.